On Friday, HD Supply Holdings Inc (NASDAQ:HDS)’s shares declined -0.66% to $34.76.
HD Supply Holdings Inc (HDS) one of the largest industrial distributors in North America, recently stated Net sales of $2.2 billion for the first quarter of fiscal 2015 ended May 3, 2015, an enhance of $127 million, or 6 percent, as contrast to the first quarter of fiscal 2014. The company believes its sales performance represents growth of about 300 to 400 basis points in excess of its market growth estimate.
Gross profit raised $46 million, or 8 percent, to $649 million for the first quarter of fiscal 2015 contrast to $603 million for the first quarter of fiscal 2014. Gross profit was 29.2 percent of Net sales for the first quarter of fiscal 2015, up about 40 basis points from 28.8 percent of Net sales for the first quarter of fiscal 2014. The improvement in gross margin as a percentage of Net sales was primarily driven by category administration initiatives and favorable product and services mix.
Operating income raised $51 million, or 44 percent, to $167 million for the first quarter of fiscal 2015 contrast to $116 million for the first quarter of fiscal 2014. Operating income as a percentage of Net sales raised about 200 basis points during the first quarter of fiscal 2015 as contrast to the first quarter of fiscal 2014. The improvement in operating income as a percentage of Net sales is a result of gross margin expansion, cost productivity initiat
HD Supply Holdings, Inc. operates as an industrial distributor in North America. The companys Facilities Maintenance segment offers electrical and lighting items, plumbing, appliances, janitorial supplies, hardware, kitchen and bath cabinets, window coverings, textiles and guest amenities, healthcare maintenance, and water and wastewater treatment products, in addition to heating, ventilating, and air conditioning products. Its Waterworks segment provides pipes, fittings, valves, hydrants, and meters for use in the construction, maintenance, and repair of water and waste-water systems, in addition to fire-protection systems; and smart meters, fusible piping solutions, and engineered treatment plant products and services.
Radius Health Inc (NASDAQ:RDUS)’s shares gained 0.60% to $60.00.
Radius Health Inc (RDUS) declared first six-month data from the ACTIVExtend study together with 25-month combined data from the phase III ACTIVE and ACTIVExtend studies on its lead candidate abaloparatide-SC. The company’s shares gained 6.5% following the declarement.
Radius Health is developing abaloparatide-SC for reducing the risk of fracture in postmenopausal women suffering from severe osteoporosis. The company stated that patients who formerly accomplished 18-months treatment with abaloparatide-SC in the phase III ACTIVE study and were receiving alendronate in the ACTIVExtend study (extension to the ACTIVE study) did not undergo new vertebral fractures during the first six-month treatment with alendronate.
The ACTIVExtend study is evaluating 24 months of standard-of-care osteoporosis administration in postmenopausal women, after they accomplished 18-month treatment with abaloparatide-SC or placebo in the ACTIVE study.
Meanwhile, Radius Health revealed new data from an exploratory analysis of major osteoporotic fractures on the ACTIVE study, which showed a 67% reduction in major osteoporotic fractures in the abaloparatide treatment group contrast to placebo. Patients in the abaloparatide arm also achieved a 53% reduction in major osteoporotic fractures contrast to Eli Lilly’s LLY Forteo.
Radius Health, Inc., a biopharmaceutical company, focuses on developing therapeutics for patients with osteoporosis and other serious endocrine-mediated diseases in the United States. The company’s lead product comprises abaloparatide SC (BA058), a novel synthetic peptide analog of parathyroid hormone-related protein that is in Phase III clinical development for use in the reduction of fractures in postmenopausal osteoporosis; and Abaloparatide-TD, a line extension of abaloparatide-SC in the form of a transdermal patch that has accomplished Phase II clinical trial, which is used to enhance bone mineral density.
At the end of Friday’s trade, Radian Group Inc (NYSE:RDN)‘s shares dipped -0.86% to $18.50.
Radian Group Inc (RDN) declared that, following the pricing of its 5.250% Senior Notes due 2020 (the 2020 Senior Notes), it has entered into privately negotiated agreements with certain of the holders (Sellers) of its 3.000% Convertible Senior Notes due 2017 (the 2017 Convertible Notes) to purchase an aggregate of $389 million principal amount of 2017 Convertible Notes for a combination of cash and shares of Radian common stock (the Convertible Purchase). Radian plans to fund the Convertible Purchase with $127 million in cash (plus accrued and unpaid interest) and by issuing to the Sellers about 28.4 million shares of common stock. Following the Convertible Purchase, which is predictable to close by June 23, 2015, subject to the satisfaction of customary closing conditions, $61 million principal amount of the 2017 Convertible Notes will remain outstanding.
In order to reduce the dilutive impact of the Convertible Purchase, Radian also intends to enter into an accelerated share repurchase program (ASR) to repurchase an aggregate of about $202 million of Radian’s common stock. Under the ASR, Radian anticipates to receive an upfront delivery of about 9.2 million shares with the total number of shares ultimately delivered to Radian to be based on the volume-weighted average price of Radian’s common stock during the term of the transaction, less a discount and subject to adjustments pursuant to the terms and conditions of the program. Radian anticipates to fund the ASR with a portion of the net proceeds from the 2020 Senior Notes.
Radian Group Inc., through its auxiliaries, provides mortgage and real estate products and services in the United States. It operates through two segments, Mortgage Insurance, and Mortgage and Real Estate Services (MRES). The Mortgage Insurance segment provides credit-related insurance coverage, principally through private mortgage insurance that protects mortgage lenders from all or a portion of default-related losses on residential mortgage loans made to home buyers, in addition to facilitates the sale of these mortgage loans in the secondary mortgage market. It offers primary mortgage insurance coverage on residential first-liens.
WhiteWave Foods Co (NYSE:WWAV), ended its Friday’s trading session with -1.47% loss, and closed at $48.84.
WhiteWave Foods Co (WWAV) a leading consumer packaged food and beverage company in North America and Europe, recently declared that it has agreed to acquire Vega, a pioneer and leader in plant-based nutrition products, for about US$550 million in cash.
Vega offers a broad range of market-leading plant-based nutrition products – primarily powdered shakes and snack bars – containing nutrient-dense, superfood ingredients. Vega’s products are all plant-based and provide a good source of protein, Omega 3s, fiber, vitamins, probiotics and antioxidants. Vega holds a strong market position in the plant-based nutrition category across Canada and the U.S., with a top-tier retail customer base and loyal consumer following ranging from general wellness-seekers to athletes. Based in Vancouver, British Columbia, Vega was founded in 2004 by President Charles Chang, and is presently majority owned by Mr. Chang and VMG Partners.
The WhiteWave Foods Company, a consumer packaged food and beverage company, manufactures, markets, distributes, and sells branded plant-based foods and beverages, salads, fruits and vegetables, coffee creamers and beverages, and dairy products and organic produce in North America and Europe. It operates in three segments: Americas Foods & Beverages, Americas Fresh Foods, and Europe Foods & Beverages.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
